Publications in collaboration with researchers from Aaron Diamond AIDS Research Center (1)

2014

  1. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

    The Lancet Infectious Diseases, Vol. 14, Núm. 7, pp. 590-599